FORT LAUDERDALE, Fla., Feb. 11, 2016 -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced the signing of a five year agreement with a Canadian pharmaceutical drug developer. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five year term in numerous global trials spanning Phase I to Phase III clinical studies.
TrialMaster was selected after an exhaustive evaluation that included OmniComm and six other leading EDC solution providers to select the replacement for their legacy EDC application. Specific evaluation emphasis was placed on fast study build time, ease of data extraction in submission ready data format, direct patient data entry and a comprehensive feature set. TrialMaster was found superior in all categories when compared to the other six competing EDC technologies. The depth and breadth of functionality, ease of contracting, and a highly responsive executive management team were significant factors in the selection of TrialMaster EDC.
Trial build time was of particular interest as this clinical development team will be responsible for building their own studies. They found TrialMaster’s rich and versatile design and build toolset easier to learn and easier to work with when compared to the competing technologies and thereby enabling faster study build times. TrialMaster will be deployed within OmniComm’s OmniCloud® for hosting and maintenance of the entire IT infrastructure, ensuring clinical data management technology is always running; data is secure, and product enhancements are rolled out seamlessly.
“We are very pleased that, across a field of highly regarded EDC technologies, OmniComm’s TrialMaster was selected as the best solution by a very knowledgeable and savvy group of clinical professionals,” states Kuno van der Post, SVP of business development, OmniComm. “We are all extremely excited to see this new client showcase our software.”
Supporting Information
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
Trademarks
OmniComm, OmniCloud, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
OmniComm Systems, Inc. 2101 West Commercial Blvd. Suite 3500 Fort Lauderdale, FL 33309 USA Phone: +1.954.473.1254 Fax: +1.954.473.1256 www.omnicomm.com


DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
Google Secures Pentagon AI Deal for Classified Projects
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 



